Gemina Laboratories Ltd. (TSE:GLAB)
:GLAB
Top Page
Gemina Laboratories Ltd.
(GLAB)
Select Model
Select Model
Rating:41Neutral
Price Target:
C$0.04
▼(-36.67% Downside)
Action:ReiteratedDate:02/26/26
The score is driven primarily by weak financial performance (minimal revenue, large losses, and negative equity), which signals elevated execution and financing risk. Technicals also weigh heavily, with the price below all key moving averages and negative MACD indicating a persistent downtrend. Valuation provides limited support because the company is loss-making (negative P/E) and has no stated dividend yield.
Positive Factors
Improved cash generation
A move from persistent cash burn to slight positive operating and free cash flow reflects operational improvement versus prior years. If sustained, even modest positive cash generation reduces near-term financing urgency and extends runway, improving strategic flexibility for R&D or commercialization steps.
Negative Factors
Minimal recurring revenue
The company lacks meaningful product or service revenue and reports negative gross profit, which undermines proof of commercial traction. Without scalable revenue, the business must rely on financing for operations, making durable margin improvement and self-funded growth unlikely absent material commercial progress.
Read all positive and negative factors
Positive Factors
Negative Factors
Improved cash generation
A move from persistent cash burn to slight positive operating and free cash flow reflects operational improvement versus prior years. If sustained, even modest positive cash generation reduces near-term financing urgency and extends runway, improving strategic flexibility for R&D or commercialization steps.
Read all positive factors
Gemina Laboratories Ltd. (GLAB) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$2.30M
Dividend YieldN/A
Average Volume (3M)13.56K
Price to Earnings (P/E)―
Beta (1Y)-0.86
Revenue GrowthN/A
EPS Growth9.06%
CountryCA
Employees6
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding76,570,910
10 Day Avg. Volume19,305
30 Day Avg. Volume13,558
Financial Highlights & Ratios
PEG Ratio0.42
Price to Book (P/B)-9.02
Price to Sales (P/S)0.00
P/FCF Ratio-30.74
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Gemina Laboratories Ltd. Business Overview & Revenue Model
Company Description
Gemina Laboratories Ltd., a biotechnology company, engages in the research, development, and commercialization of in-vitro diagnostics in Canada. The company develops novel surface functionalization chemistries for the detection of pathogens and b...
How the Company Makes Money
Gemina Laboratories Ltd. generates revenue primarily through the sale of its diagnostic products to healthcare providers, laboratories, and other medical institutions. The company may also engage in partnerships and collaborations with other biote...
Gemina Laboratories Ltd. Financial Statement Overview
Summary
Income Statement
7
Very Negative
Balance Sheet
14
Very Negative
Cash Flow
28
Negative
| Breakdown | TTM | Apr 2025 | Apr 2024 | Apr 2023 | Apr 2022 | Jan 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 10.88K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -23.89K | -113.24K | -93.37K | -50.28K | -43.83K | -12.09K |
| EBITDA | -2.78M | -3.80M | -5.18M | -5.93M | -4.69M | -819.60K |
| Net Income | -2.93M | -4.07M | -5.22M | -5.98M | -4.74M | -834.15K |
Balance Sheet | ||||||
| Total Assets | 1.11M | 1.44M | 1.46M | 1.87M | 1.42M | 2.53M |
| Cash, Cash Equivalents and Short-Term Investments | -613.00 | 703.00 | 990.00 | 83.09K | 1.17M | 898.05K |
| Total Debt | 240.11K | 1.27M | 485.33K | 240.84K | 46.08K | 98.13K |
| Total Liabilities | 6.25M | 5.87M | 3.04M | 1.95M | 475.92K | 2.37M |
| Stockholders Equity | -5.14M | -4.44M | -1.59M | -71.81K | 944.23K | 159.96K |
Cash Flow | ||||||
| Free Cash Flow | 586.00 | -1.30M | -3.29M | -4.59M | -3.88M | -319.09K |
| Operating Cash Flow | 582.00 | -1.30M | -3.24M | -4.51M | -3.87M | -319.09K |
| Investing Cash Flow | 18.42K | 18.42K | -41.35K | -505.07K | 8.20K | 13.91K |
| Financing Cash Flow | -61.22K | 1.28M | 3.20M | 3.94M | 4.14M | 2.72M |
Gemina Laboratories Ltd. Technical Analysis
Negative
0.06
Price Trends
0.05
Negative
0.13
Negative
0.39
Negative
Market Momentum
>-0.01
Negative
14.27
Positive
>-0.01
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:GLAB, the sentiment is Negative. The current price of 0.06 is above the 20-day moving average (MA) of 0.04, above the 50-day MA of 0.05, and below the 200-day MA of 0.39, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 14.27 is Positive, neither overbought nor oversold. The STOCH value of >-0.01 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:GLAB.
Gemina Laboratories Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | C$1.39M | -6.62 | -107.76% | ― | ― | 34.22% | |
45 Neutral | C$4.41M | -4.13 | -41.36% | ― | -50.89% | -32.33% | |
44 Neutral | C$3.47M | -1.36 | ― | ― | ― | ― | |
41 Neutral | C$2.30M | -22.65 | ― | ― | ― | 9.06% |
* Healthcare Sector Average
TSE:GLAB
Gemina Laboratories Ltd.
0.03
-1.21
-97.58%
TSE:HEAL
Restart Life Sciences
0.10
0.00
0.00%
TSE:ENBI
Entheon Biomedical
0.10
-0.04
-31.03%
TSE:MYND
MYND Life Sciences
0.07
0.04
133.33%
TSE:IBO
Universal Ibogaine Inc
0.01
-0.01
-50.00%
TSE:MOOD
Doseology Sciences
0.55
0.18
48.65%
Gemina Laboratories Ltd. Corporate Events
Business Operations and StrategyDelistings and Listing ChangesPrivate Placements and FinancingShareholder Meetings
Gemina Laboratories Plans Secured Debenture Financing and Voluntary CSE Delisting
Negative
Dec 30, 2025
Gemina Laboratories Ltd. plans to raise between $1 million and $3 million through a non-brokered private placement of secured, non-convertible debentures, each with a $1,000 face value, a 12-month term and an 18% annual interest rate, secured by a...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.